Literature DB >> 18552138

Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy.

Barbara Sotgia1, Roberto Sciagrà, Iacopo Olivotto, Giancarlo Casolo, Luigi Rega, Irene Betti, Alberto Pupi, Paolo G Camici, Franco Cecchi.   

Abstract

UNLABELLED: To clarify the spatial relationship between coronary microvascular dysfunction and myocardial fibrosis in hypertrophic cardiomyopathy (HCM), we compared the measurement of hyperemic myocardial blood flow (hMBF) by PET with the extent of delayed contrast enhancement (DCE) detected by MRI.
METHODS: In 34 patients with HCM, PET was performed using (13)N-labeled ammonia during hyperemia induced by intravenous dipyridamole. DCE and systolic thickening were assessed by MRI. Left ventricular myocardial segments were classified as with DCE, either transmural (DCE-T) or nontransmural (DCE-NT), and without DCE, either contiguous to DCE segments (NoDCE-C) or remote from them (NoDCE-R).
RESULTS: In the group with DCE, hMBF was significantly lower than in the group without DCE (1.81 +/- 0.94 vs. 2.13 +/- 1.11 mL/min/g; P < 0.001). DCE-T segments had lower hMBF than did DCE-NT segments (1.43 +/- 0.52 vs. 1.91 +/- 1 mL/min/g, P < 0.001). Similarly, NoDCE-C segments had lower hMBF than did NoDCE-R (1.98 +/- 1.10 vs. 2.29 +/- 1.10 mL/min/g, P < 0.01) and had no significant difference from DCE-NT segments. Severe coronary microvascular dysfunction (hMBF in the lowest tertile of all segments) was more prevalent among NoDCE-C than NoDCE-R segments (33% vs. 24%, P < 0.05). Systolic thickening was inversely correlated with percentage transmurality of DCE (Spearman rho = -0.37, P < 0.0001) and directly correlated with hMBF (Spearman rho = 0.20, P < 0.0001).
CONCLUSION: In myocardial segments exhibiting DCE, hMBF is reduced. DCE extent is inversely correlated and hMBF directly correlated with systolic thickening. In segments without DCE but contiguous to DCE areas, hMBF is significantly lower than in those remote from DCE and is similar to the value obtained in nontransmural DCE segments. These results suggest that increasing degrees of coronary microvascular dysfunction might play a causative role for myocardial fibrosis in HCM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18552138     DOI: 10.2967/jnumed.107.050138

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  21 in total

1.  Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype?

Authors:  Paco E Bravo; Hong-Chang Luo; Iraklis Pozios; Stefan L Zimmerman; Celia Pamela Corona-Villalobos; Lars Sorensen; Ihab R Kamel; David A Bluemke; Richard L Wahl; M Roselle Abraham; Theodore P Abraham
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-06-14       Impact factor: 6.875

2.  Myocardial steatosis as a possible mechanistic link between diastolic dysfunction and coronary microvascular dysfunction in women.

Authors:  Janet Wei; Michael D Nelson; Edward W Szczepaniak; Laura Smith; Puja K Mehta; Louise E J Thomson; Daniel S Berman; Debiao Li; C Noel Bairey Merz; Lidia S Szczepaniak
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-30       Impact factor: 4.733

3.  Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal.

Authors:  Helga Castagnoli; Cecilia Ferrantini; Raffaele Coppini; Alessandro Passeri; Katia Baldini; Valentina Berti; Franco Cecchi; Iacopo Olivotto; Roberto Sciagrà
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-16       Impact factor: 9.236

4.  Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy.

Authors:  Paco E Bravo; Stefan L Zimmerman; Hong-Chang Luo; Iraklis Pozios; Mahadevan Rajaram; Aurélio Pinheiro; Charles Steenbergen; Ihab R Kamel; Richard L Wahl; David A Bluemke; Frank M Bengel; M Roselle Abraham; Theodore P Abraham
Journal:  Circ Cardiovasc Imaging       Date:  2013-02-15       Impact factor: 7.792

Review 5.  Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Aurelio Sgalambro; Massimo Baldi; Barbara Sotgia; Davide Antoniucci; Paolo G Camici; Roberto Sciagrà; Iacopo Olivotto
Journal:  J Cardiovasc Transl Res       Date:  2009-11-03       Impact factor: 4.132

Review 6.  The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice.

Authors:  Iacopo Olivotto; Francesca Girolami; Stefano Nistri; Alessandra Rossi; Luigi Rega; Francesca Garbini; Camilla Grifoni; Franco Cecchi; Magdi H Yacoub
Journal:  J Cardiovasc Transl Res       Date:  2009-10-27       Impact factor: 4.132

Review 7.  The current and emerging role of cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy.

Authors:  Martin S Maron
Journal:  J Cardiovasc Transl Res       Date:  2009-11-07       Impact factor: 4.132

Review 8.  Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies.

Authors:  Paco E Bravo; Marcelo F Di Carli; Sharmila Dorbala
Journal:  Heart Fail Rev       Date:  2017-07       Impact factor: 4.214

9.  Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?

Authors:  Paco E Bravo
Journal:  J Nucl Cardiol       Date:  2018-05-14       Impact factor: 5.952

Review 10.  Coronary arterial vasculature in the pathophysiology of hypertrophic cardiomyopathy.

Authors:  Richard J Marszalek; R John Solaro; Beata M Wolska
Journal:  Pflugers Arch       Date:  2018-10-29       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.